Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 April 2012 A study has shown that two commercial electronic prescribing systems were associated with a statistically significant reduction in total prescribing error rates (66.1%, 57.5% and 60.5% […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5 May 2011 An ethnographic case study of four GP practices found that repeat prescribing was a complex, technology-supported social practice, requiring collaboration between administrative staff and clinicians, with […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 13 September 2011 Summary In July 2011 the learning report from the Health Foundation project ‘Making care safer – Improving medication safety for people in care homes: thoughts and […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24 August 2011 Following a review of safety data, the US FDA has restricted the use of simvastatin▼* 80 mg to reduce the risk of muscle damage (myopathy). The […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20 July 2011 An FDA meta-analysis of 31 randomised controlled trials found that treatment with an angiotensin-2 receptor antagonist (A2RA) does not increase the risk of cancer. Level of […]